Meeting
2012 ASCO Annual Meeting
Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.
Authors
Irene Brana
Princess Margaret Hospital, Toronto, ON, Canada
Irene Brana , Jhanelle Elaine Gray , Paul Haluska , Raanan Berger , Talia Golan , Mary Elizabeth Jones , Alexandra Gunchenko , Jonathan D. Cheng , Lillian L. Siu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
PI3-Akt-mTOR Pathway
Clinical Trial Registration Number
NCT01243762
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3027)
DOI
10.1200/jco.2012.30.15_suppl.3027
Abstract #
3027
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2021 ASCO Annual Meeting
Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies.
First Author: Niamh Coleman
Poster
2018 ASCO Annual Meeting
Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors.
First Author: Jennifer Rachel Eads
Poster
2015 ASCO Annual Meeting
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
First Author: Rebecca Sophie Kristeleit